J.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE
ORM PTO-1449

Sheet	1	of	2

LIST OF PRIOR ART CITED BY APPLICANT

ATTY. DOCKET:	SERIAL NO.:	38
17095CIPCON(AP)	Not assigned	165
APPLICANT:	COMBINATIONS OF PROSTAGLANDINS AND	20
Garst	BRIMONIDINE OR DERIVATIVES THEREOF	5 =
FILING DATE:	GROUP:	
Submitted herewith	Not assigned	

			U.S. PATI	ENT DOCUMENTS			
*EXAMINE		DOCUMENT	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
R INITIAL		NO.					(if applicable)
2.6	AA	4,599,353	7/8/1986	Bito			
2.5	AB	4,994,274	2/19/1991	Chan et al			
ZF	AC	3,890,319	6/17/1975	Danielewicz et al			
2-6	AD	4,029,792	6/14/1977	Danielewicz et al			
25	AE	5,173,298	12/22/1992	Meadows			
2-8-	AF	5,292,517	3/8/1994	Chang			
2-6	AG	5,021,416	6/4/1991	Gluchowski			
2-F	AH	5,091,528	2/25/1992	Gluchowski			
2.6	AI	4,291,175	9/22/1981	Wissner et al			
2.5	AJ	4,321,405	3/23/1992	Weiss			
25	AK	4,343,949	8/10/1982	Bernardy et al			
2.6	AL	4,614,825	9/30/1986	Snitman et al			
7.6	AM	4,029,681	6/14/1977	Smith			
				MEN IN DO OUR (EN INC			

FOREIGN PATENT DOCUMENTS

					TIENT DOCOMENTS			
			DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATIO
								N (yes/no)
2.	F	AN	544,899	1/7/1993	EPO			
7.6	_	AO	364,417	4/18/1990	EPO			
7.		AP	3,923,797	1/24/1991	DE)		
2.	Ä	AQ	85/02841	7/4/1985	WO			
7.	7	AR	299,914	1/18/1989	EPO			
2-	-	AS	399,839	11/28/1990	EPO		-	i i
201	6	AT	91/14428	10/3/1991	WO			
2.	F	AU	289,349	11/2/1988	EPO			
20	4	AV	366,279	5/2/1990	EPO			
7.	$c \perp$	AW	94/08585	4/28/1994	PCT			

OTHER PRIOR ART


(Including Author, Title, Date, Pertinent Pages, etc.)

Z.C. AX	Hurvitz et al, Drugs, 41(4), 514-532 (1991),"New Developments in the Drug Treatment of Glaucoma"
Z. FAY	Bito et al, "The Ocular Effects of Eicosanoids and Other Autacoids: Historic Background and the Need for a Broader Perspective", The Ocular Effects of Prostaglandins and Other Eicosanoids, Alan R. Liss, Inc., New York: 1989, 1-13,

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE FORM PTO-1449

LIST OF PRIOR ART CITED BY APPLICANT

ATTY. DOCKET: 17095FWCCPACIP(AP)	SERIAL NO.: Not assigned
APPLICANT: Garst	COMBINATIONS OF PROSTAGLANDINS AND BRIMONIDINE OR DERIVATIVES THEREOF
FILING DATE:	GROUP:
Submitted herewith	Not assigned

U.S. PATENT DOCUMENTS

1		DOCUMENT	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
		NO.					(if applicable)
2-F	BA	4,097,489	5/27/1978	Bundy			
2-6	BB	4,288,616	9/8/1981	Sih			
2.6	BC	3,755,426	8/28/1973	Strike et al			
26	BC	4,576,962	3/18/1986	Matthews			
ZF	BF	5,093,329	3/3/1992	Woodward			
2.5	BG	5,856,329	1/5/1999	Wheeler et al		_	

FOREIGN PATENT DOCUMENTS

	DOCUMENT NO.	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATIO N (yes/no)

OTHER PRIOR ART

(Including Author, Title, Date, Pertinent Pages, etc.)

Z.L	CA	Searle, J.B., "Pharmacological Advances in the Treatment of Glaucoma", Drugs Aging, Sept.
C. F		1994, 5 (3) P 156-70, New Zealand
2- C	СВ	Yavitz, "LASIK study shows brimonidine provides neuroprotective effect", Ocul Surg News
		1999 Sep 1; 17(17):28
2.6	CC	Yuksel et al, "The Short-Term Effect of Adding Brimonidine 0.2% to Timolol Treatment in
		Patients with Open-Angle Glaucoma", Ophthalmologica 1999; 213(4); 228-233
2-	CD	Yoles et al, "α2-Adrenoreceptor Agonists are Neuroprotective in a Rat Model of Optic Nerve
()		Degeneration", IOVS, January 1999, Vol. 40, No. 1, pages 65-73
		 7

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.